FinTechFunding

MGC Pharmaceuticals: Completes glioblastoma study

MGC Pharmaceuticals Completes glioblastoma study

  • MGC Pharmaceuticals (MXC) completes a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma
  • The study was undertaken between 2019 and 2022, initially using a formulation that included THC but was later replaced with cannabigerol (CBG)
  • Over 5800 cell tests were collected from 18 patients to determine the most effective concentrations and ratios of cannabidiol (CBD) and CBG in treatment
  • The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and determined the most effective CBD:CBG ratio
  • MGC Pharma ends the day 35.3 per cent in the green with shares trading at 2.3 cents
Previous article
Temenos: Launches a Dynamic NAV Oversight and Contingency Solution
Next article
Redcastle Resources: Completes RC drilling at namesake project
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing.Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...
FinTech

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users.Highlights: Tether has introduced a new stablecoin wallet.The wallet...
FinTech

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime.Highlights: FCA partners with Turing Institute to combat money...
FinTech

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions.Highlights: Spektr raises $20 million to enhance its AI...